Ra capital management, 10% owner, acquires $455,725 Artiva stock

RA Capital Management, L.P., a 10% owner and director of Artiva Biotherapeutics, Inc. (), acquired common stock totaling $455,725 through multiple transactions in late July 2026. The purchases were made at weighted average prices ranging from $9.93 to $9.99 per share. The investment comes as ARTV shares have surged 257% over the past year, with the stock currently trading at $10.10 and carrying a market cap of $507 million. According to InvestingPro analysis, analysts maintain a strong buy consensus with price targets ranging from $23 to $41.

On July 29, 2026, RA Capital Management, L.P. purchased 20,824 shares of Artiva Biotherapeutics common stock at a weighted average price of $9.99 per share. These shares were acquired in multiple transactions with prices ranging from $9.84 to $10.00. The shares are indirectly held by RA Capital Healthcare Fund, L.P.

Two days later, on July 31, 2026, an additional 24,944 shares were acquired at a weighted average price of $9.93 per share. These shares were purchased in multiple transactions at prices ranging from $9.82 to $9.97. Following these transactions, RA Capital Management, L.P. beneficially owns a total of 17,329,570 shares of Artiva Biotherapeutics common stock indirectly.

RA Capital Management, L.P. serves as the investment manager for several entities, including RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., and a separately managed account, through which these shares are indirectly held. Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members of RA Capital Management GP, LLC, the general partner of RA Capital Management, L.P. They, along with the various funds, disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest. Laura Stoppel, a Partner of RA Capital Management, L.P., also serves on Artiva Biotherapeutics’ board of directors.

In other recent news, Artiva Biotherapeutics received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its rheumatoid arthritis treatment, AlloNK, in combination with rituximab. This designation allows the company to benefit from expedited development and review processes, enhancing early and frequent interactions with the FDA. Additionally, Artiva presented clinical data at the European Alliance of Associations for Rheumatology Congress, showing that 71% of patients with rheumatoid arthritis achieved a significant improvement after six months of treatment with AlloNK and rituximab.

Cantor Fitzgerald reiterated its Overweight rating on Artiva Biotherapeutics, maintaining a price target of $40.00. The firm recently hosted a webinar with Artiva’s CEO, Fred Aslan, to discuss the company’s safety profile and strategy. In corporate developments, Artiva announced executive changes, with Diego Miralles, M.D. resigning from the board to become the President and Head of Research and Development. His departure reduced the board from eight to seven members, although it was not due to any disagreement with the company.